https://www.selleckchem.com/pr....oducts/Monensin-sodi
79, 95% confidence interval (CI) 0.66-0.95; P = 0.01]. Besides, Kaplan-Meier plots showed significant cause-specific survival advantage of NRT in intestinal type (P 0.001), but not in diffuse type (P = 0.11) for T N patients. In the multivariate competing risk model, NRT still showed survival advantage only in T N patients (subdistribution HR 0.77; 95% CI 0.64-0.93; P = 0.006), but not in other subgroups. NRT might benefit resectable gastric and GEJ cancer patients of T3-4 stages with positive lymph nodes, parti
Like
Comment
Share
